192 related articles for article (PubMed ID: 34110068)
21. Intertumoral Heterogeneity of CD3
Yoon HH; Shi Q; Heying EN; Muranyi A; Bredno J; Ough F; Djalilvand A; Clements J; Bowermaster R; Liu WW; Barnes M; Alberts SR; Shanmugam K; Sinicrope FA
Clin Cancer Res; 2019 Jan; 25(1):125-133. PubMed ID: 30301825
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and predictive role of DNA mismatch repair status in stage II-III colorectal cancer: A systematic review and meta-analysis.
Deng Z; Qin Y; Wang J; Wang G; Lang X; Jiang J; Xie K; Zhang W; Xu H; Shu Y; Zhang Y
Clin Genet; 2020 Jan; 97(1):25-38. PubMed ID: 31432497
[TBL] [Abstract][Full Text] [Related]
23. Impact of age and mismatch repair status on survival in colorectal cancer.
Li P; Xiao ZT; Braciak TA; Ou QJ; Chen G; Oduncu FS
Cancer Med; 2017 May; 6(5):975-981. PubMed ID: 28345223
[TBL] [Abstract][Full Text] [Related]
24. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
[TBL] [Abstract][Full Text] [Related]
25. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.
Liu S; Kong P; Wang X; Yang L; Jiang C; He W; Quan Q; Huang J; Xie Q; Xia X; Zhang B; Xia L
Oncol Lett; 2019 Feb; 17(2):2335-2343. PubMed ID: 30675299
[TBL] [Abstract][Full Text] [Related]
26. Accuracy of four mononucleotide-repeat markers for the identification of DNA mismatch-repair deficiency in solid tumors.
Takehara Y; Nagasaka T; Nyuya A; Haruma T; Haraga J; Mori Y; Nakamura K; Fujiwara T; Boland CR; Goel A
J Transl Med; 2018 Jan; 16(1):5. PubMed ID: 29329588
[TBL] [Abstract][Full Text] [Related]
27. Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer.
van der Heide DM; Turaga KK; Chan CHF; Sherman SK
J Surg Res; 2021 Oct; 266():104-112. PubMed ID: 33989889
[TBL] [Abstract][Full Text] [Related]
28. Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort.
Zwart K; van der Baan FH; Punt CJA; Wensink GE; Bolhuis K; Laclé MM; van Grevenstein WMU; Hagendoorn J; de Hingh IH; Koopman M; Vink G; Roodhart J
Ann Surg Oncol; 2023 Oct; 30(11):6762-6770. PubMed ID: 37528303
[TBL] [Abstract][Full Text] [Related]
29. [Correlation between mismatch repair proteins status and clinicopathological characteristics in sporadic colorectal cancer patients].
Xiao ZT; Zhang RX; Zhao Y; Peng JH; Lu SX; Zhang HZ; Ding PR; Wu XJ; Lu ZH; Li LR; Wan DS; Pan ZZ; Chen G
Zhonghua Yi Xue Za Zhi; 2017 Apr; 97(16):1248-1251. PubMed ID: 28441855
[No Abstract] [Full Text] [Related]
30. Systemic Inflammatory Markers of Resectable Colorectal Cancer Patients with Different Mismatch Repair Gene Status.
Li J; Zhang Y; Xu Q; Wang G; Jiang L; Wei Q; Luo C; Chen L; Ying J
Cancer Manag Res; 2021; 13():2925-2935. PubMed ID: 33833576
[TBL] [Abstract][Full Text] [Related]
31. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.
Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS
Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649
[TBL] [Abstract][Full Text] [Related]
32. Systemic neutrophil lymphocyte ratio and mismatch repair status in colorectal cancer patients: correlation and prognostic value.
He WZ; Hu WM; Kong PF; Yang L; Yang YZ; Xie QK; Jiang C; Yin CX; Qiu HJ; Zhang B; Zhang HZ; Xia LP
J Cancer; 2018; 9(17):3093-3100. PubMed ID: 30210632
[No Abstract] [Full Text] [Related]
33. Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial.
Barrow P; Richman SD; Wallace AJ; Handley K; Hutchins GGA; Kerr D; Magill L; Evans DG; Gray R; Quirke P; Hill J
Histopathology; 2019 Aug; 75(2):236-246. PubMed ID: 31062389
[TBL] [Abstract][Full Text] [Related]
34. Systematic immunohistochemical screening for mismatch repair and ERCC1 gene expression from colorectal cancers in China: Clinicopathological characteristics and effects on survival.
Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
PLoS One; 2017; 12(8):e0181615. PubMed ID: 28767665
[TBL] [Abstract][Full Text] [Related]
35. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.
Antill Y; Kok PS; Robledo K; Yip S; Cummins M; Smith D; Spurdle A; Barnes E; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Andrews J; Stockler MR; Mileshkin L;
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103352
[TBL] [Abstract][Full Text] [Related]
36. Development of novel models for predicting mismatch repair protein deficiency and relevant disease-free survival in colorectal cancer patients.
Xu Y; Li Y; Zhu Z; Yang J; Tan Y; Wang Y; Xu X
Int J Colorectal Dis; 2022 Jun; 37(6):1449-1464. PubMed ID: 35482069
[TBL] [Abstract][Full Text] [Related]
37. Evidence for an Association of ERCC1 Expression and Mismatch Repair Status with Overall Survival in Colorectal Cancer Patients.
Li P; Xiao ZT; Braciak TA; Ou QJ; Chen G; Oduncu FS
Oncol Res Treat; 2017; 40(11):702-706. PubMed ID: 29065415
[TBL] [Abstract][Full Text] [Related]
38. A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research.
Wensink E; Bond M; Kucukkose E; May A; Vink G; Koopman M; Kranenburg O; Roodhart J
Cancer Treat Rev; 2021 Apr; 95():102174. PubMed ID: 33721596
[TBL] [Abstract][Full Text] [Related]
39. Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients.
Liu SS; Yang YZ; Jiang C; Quan Q; Xie QK; Wang XP; He WZ; Rong YM; Chen P; Yang Q; Yang L; Zhang B; Xia XJ; Kong PF; Xia LP
J Transl Med; 2018 Jul; 16(1):195. PubMed ID: 30005666
[TBL] [Abstract][Full Text] [Related]
40. Mitochondrial DNA copy number plays opposing roles in T-lymphocyte infiltration of colorectal cancer based on mismatch repair status: new directions for immunotherapy?
Chen M; Liu H; Liang W; Huang P; Ye F; Cai Y; Liang Z; Xiong L; Kang L; Huang L
Br J Cancer; 2024 Mar; 130(5):798-807. PubMed ID: 38218920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]